Navigation Links
Researchers develop new tool to predict who will use microbicides
Date:3/3/2008

Providence, RI Using a new tool designed to measure a womans willingness to use a microbicide (topical gels designed to prevent the sexual transmission of HIV), researchers at The Miriam Hospital and Brown University found that women who have used protective methods in the past, and those with casual sexual partners were more willing to use a microbicide compared to their peers.

Although a safe and effective microbicide has not been identified yet, several candidates are now undergoing clinical efficacy trials. The complete study is published in the November 2007 issue of Healthy Psychology.

The results may seem to be an obvious finding, but they are important because science has very little direct evidence of what characteristics and situations in womens lives would make them more likely to want to use a microbicide to prevent HIV infection, says lead author Kathleen M. Morrow, Ph.D., a psychologist at The Miriam Hospitals Centers for Behavioral and Preventive Medicine and an assistant professor at The Warren Alpert Medical School at Brown University.

An effective microbicide would have little impact on the rate of HIV transmission if it was unacceptable to women, i.e. if it makes their sexual experiences less pleasurable, or gets in the way, women wont use it, no matter how effective it is says Morrow.

In an attempt to understand the circumstances that compel women to decide to protect themselves or not, Morrow and her team designed the Willingness to Use Microbicides scale. The scale consists of a series of questions about particular situations, e.g. would you have wanted to use a microbicide the last time you had sex with your partner, as well as product-related questions, e.g. if a microbicide costs about as much as a male condom, would you have used it?

The questionnaire was given to 531 women in Connecticut, Massachusetts, New York, and Rhode Island. Eligibility criteria required that the women be 18-
'/>"/>

Contact: Megan Martin
mmartin@lifespan.org
401-793-7484
Lifespan
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)... Youngest Babies, This Type of Blood Cancer Is Most ... 5 Pediatric oncologists have identified specific genes, dubbed ... an often-fatal form of leukemia in infants. By more ... predict which infants may benefit from particular treatments. ...
(Date:12/5/2009)... ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 ... their 40th birthday without ever tying the knot, since research ... married folks. And, um, isn,t there something wrong with those ... A new study looking at psychological measures shows that never-married ...
(Date:12/5/2009)... by the National Association of Certified Professional Midwives ... for Midwifery (CfM), International Center for Traditional Childbearing ... the Midwifery Education Accreditation Council (MEAC). To ... Campaign to secure federal recognition of CPMs language ...
(Date:12/4/2009)... Care Investment Trust Inc. (NYSE: CRE ... Directors has declared a dividend of $0.17 per share of common ... common shareholders of record on December 14, 2009. ... Inc. is a real estate investment and finance company investing in ...
(Date:12/4/2009)... World Assurance,Company Holdings, Ltd (NYSE: AWH ) ... and Jack Sennott, Executive Vice,President and Chief Corporate Strategy ... Financial Services Conference being held at the Goldman,Sachs Conference ... 2009. ,, About Allied World ...
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
... to recent rises in caesarean section rates, according to ... University. , The findings come from an analysis of ... team under Professor Gordon Smith, at the University,s Department ... more than 500,000 entries collected by the Scottish Morbidity ...
... depression, drug abuse, study says , , WEDNESDAY, July 2 ... in "sacred mushrooms" can last more than a year, ... investigations may lead to new ways to help people ... , In a previous study, the researchers gave psilocybin ...
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... is scheduled to present at the,Collins Stewart Growth ... Oriental Hotel in New York City., SuperGen,s ...
... CLARA, Calif., July 2 Align Technology,Inc. (Nasdaq: ... proprietary method of,straightening teeth without wires and brackets, ... 2008 financial results on Tuesday, July,29, 2008, after ... released,over PR Newswire and First Call and will ...
... 2 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX:,CUR), a life ... laboratory services, announced today that Dr. Timothy,J. Holzer, ... Dr. Scott,Waldman, from Thomas Jefferson University, were speakers ... session at the Eastern Cooperative Oncology,Group (ECOG), one ...
... Toronto Stock Exchange Symbol: CYT, MONTREAL, ... CYT), the global leader in cryotherapy products ... of Frank Vandeputte as Vice,President, Europe. Based ... Netherlands, Mr. Vandeputte will be responsible for ...
Other Medicine News:Health News:Major rise in Caesarean sections linked to impaired womb function with age 2Health News:Hallucinogen Gives Lasting Spiritual Boost 2Health News:SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008 2Health News:Align Technology to Announce Second Quarter Fiscal 2008 Results on July 29 2Health News:DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group 2Health News:DiagnoCure's GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group 3Health News:CryoCath Appoints Vice President, Europe 2
(Date:12/4/2009)... Dec. 4 Drs. Neal Shore and E. David ... the additional analysis of secondary end points of biochemical ... FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in ... Prostate cancer patients who received FIRMAGON 240/80 mg/month ...
(Date:12/4/2009)... (NYSE: AZN ) today announced that the ... SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive ... Disorder (MDD). SEROQUEL XR is the only medication in ... major depressive disorder as adjunctive therapy and acute depressive ...
(Date:12/3/2009)... , a leading primary research firm, today announced the launch ... that monitors and projects trends and market share in the ... captures actual patient usage for 87 different Sleep Apnea mask ... providers going back to January 2006. In the most ...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2German Alliance for Industrial Biotechnology Debuts in Montreal 12992 1German Alliance for Industrial Biotechnology Debuts in Montreal 12992 2Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 1Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 2Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 3Sparta Systems TrackWise 28R 29 Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 12990 4Dynamic molecular mechanism to keep brain activity stable 51464 1
... SEATTLE, Aug. 22 Vical Incorporated (Nasdaq:,VICL) announced ... vaccine Phase 2a,clinical trials, using a plasmid DNA ... and manufactured by Vical, reinforced previously,reported Phase 1 ... was safe and well-tolerated, and was effective in ...
... Trial Examines Single, Higher, More Concentrated Dose of ... ... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced enrollment of the ... with,Mini-dose Alfimeprase-3) trial evaluating lead product candidate,alfimeprase, for the treatment of ...
Other Medicine Technology:Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 2Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 2Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 3Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion 4
The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor....
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
The HypercleanTM 1 is a versatile, durable fume handling station. The Hyperclean 1 fume handling station unit comes complete with one (1) blower unit and one (1) charcoal filter....
... 2 fume containment system ... benchtop equipment. Even large ... inside the Hyperclean 2. ... system unit comes complete with ...
Medicine Products: